The Gene Therapy No One Is Talking About: San Rocco and the Cost of Silence in Sickle Cell Care

As the biotech press dissects operational delays facing Vertex Pharmaceuticals’ CRISPR-based therapy for sickle cell disease, one gene therapy program has remained conspicuously absent from mainstream coverage: San Rocco Therapeutics (formerly Errant Gene Therapy). This is a venture that TrialSite News has showcased since our full first year in 2019. That silence is notable—not because San Rocco is promotional, well-capitalized, or media-savvy, but precisely because it is none of those things…

View the rest of the article here

View the PDF